Orbis Allan Gray’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Orbis Allan Gray’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-121,479	Closed	-$273K	–	67
2020 Q3	$273K	Sell	121,479 -5,424,033	-98%	-$15.5M	﹤0.01%	61
2020 Q2	$19.9M	Buy	5,545,512 +41,512	+0.8%	+$150K	0.15%	37
2020 Q1	$20.9M	Sell	5,504,000 -10,627	-0.2%	-$35K	0.2%	32
2019 Q4	$16.6M	Buy	+5,514,627	New	+$14.3M	0.12%	41

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Orbis Allan Gray's BMY.RT Position: Q4 2020 in Review

Orbis Allan Gray sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 121,479 shares — an estimated $273K sold.

Orbis Allan Gray first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $20.9M in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Orbis Allan Gray reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Orbis Allan Gray sold 121,479 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $273K.
Orbis Allan Gray first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Orbis Allan Gray's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $20.9M in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Orbis Allan Gray's 13F filing for Q4 2020, filed 16 Feb 2021.